Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized open-label study of abemaciclib alone or in combination versus standard chemotherapy in previously treated metastatic pancreatic adenocarcinoma
MOH_2017-02-08_000091Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of abemaciclib in pancreatic adenocarcinoma (PDAC) (4 arms), sponsored by Eli Lilly and Company. Primary endpoints: Safety and adverse events and Comparative antitumor outcomes versus standard therapy. Started Nov 2016; status: completed.
02
Drugs
abemaciclib
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on MOH_2017-02-08_000091.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-02-08_000091.